Cystatin C Concentration As a Risk Factor for Heart Failure in Older Adults
Overview
Authors
Affiliations
Background: Previous studies that evaluated the association of kidney function with incident heart failure may be limited by the insensitivity of serum creatinine concentration for detecting abnormal kidney function.
Objective: To compare serum concentrations of cystatin C (a novel marker of kidney function) and creatinine as predictors of incident heart failure.
Design: Observational study based on measurement of serum cystatin C from frozen sera obtained at the 1992-1993 visit of the Cardiovascular Health Study. Follow-up occurred every 6 months.
Setting: Adults 65 years of age or older from 4 communities in the United States.
Participants: 4384 persons without previous heart failure who had measurements of serum cystatin C and serum creatinine.
Measurements: Incident heart failure.
Results: The mean (+/-SD) serum concentrations of cystatin C and creatinine were 82 +/- 25 nmol/L (1.10 +/- 0.33 mg/L) and 89 +/- 34 micromol/L (1.01 +/- 0.39 mg/dL), respectively. During a median follow-up of 8.3 years (maximum, 9.1 years), 763 (17%) participants developed heart failure. After adjustment for demographic factors, traditional and novel cardiovascular risk factors, cardiovascular disease status, and medication use, sequential quintiles of cystatin C concentration were associated with a stepwise increased risk for heart failure in Cox proportional hazards models (hazard ratios, 1.0 [reference], 1.30 [95% CI, 0.96 to 1.75], 1.44 [CI, 1.07 to 1.94], 1.58 [CI, 1.18 to 2.12], and 2.16 [CI, 1.61 to 2.91]). In contrast, quintiles of serum creatinine concentration were not associated with risk for heart failure in adjusted analysis (hazard ratios, 1.0 [reference], 0.77 [CI, 0.59 to 1.01], 0.85 [CI, 0.64 to 1.13], 0.97 [CI, 0.72 to 1.29], and 1.14 [CI, 0.87 to 1.49]).
Limitations: The mechanism by which cystatin C concentration predicts risk for heart failure remains unclear.
Conclusions: The cystatin C concentration is an independent risk factor for heart failure in older adults and appears to provide a better measure of risk assessment than the serum creatinine concentration. *For a full list of participating Cardiovascular Health Study investigators and institutions, see http://www.chs-nhlbi.org.
Flaherty C, Surapaneni A, Seegmiller J, Coresh J, Grams M, Ballew S Kidney Med. 2024; 6(10):100893.
PMID: 39319210 PMC: 11420509. DOI: 10.1016/j.xkme.2024.100893.
Heart Failure: Is There an Ideal Biomarker?.
Clemente G, Soldano J, Tuttolomondo A Rev Cardiovasc Med. 2024; 24(11):310.
PMID: 39076445 PMC: 11272844. DOI: 10.31083/j.rcm2411310.
Prevention of Heart Failure in Patients with Chronic Kidney Disease.
Raghban A, Kirsop J, Tang W Curr Cardiovasc Risk Rep. 2024; 9(1).
PMID: 38993263 PMC: 11238633. DOI: 10.1007/s12170-014-0428-z.
Huang C, Lu J, Yang J, Wang Z, Hang D, Fu Z Front Mol Biosci. 2024; 11:1209349.
PMID: 38725873 PMC: 11079135. DOI: 10.3389/fmolb.2024.1209349.
Fu E, Carrero J, Sang Y, Evans M, Ishigami J, Inker L Ann Intern Med. 2024; 177(3):269-279.
PMID: 38285982 PMC: 11079939. DOI: 10.7326/M23-1138.